Last reviewed · How we verify
Standard of Care (Part 1)
Standard of Care (Part 1) is a Small molecule drug developed by CalciMedica, Inc.. It is currently FDA-approved. Also known as: Placebo-Injectable Emulsion, Sinemet.
Standard of Care (Part 1) refers to the established first-line treatment protocol for a given condition, which varies by indication and is not a specific drug entity.
At a glance
| Generic name | Standard of Care (Part 1) |
|---|---|
| Also known as | Placebo-Injectable Emulsion, Sinemet |
| Sponsor | CalciMedica, Inc. |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
This is a regulatory/clinical designation rather than a discrete pharmaceutical agent. 'Standard of Care' denotes the accepted medical treatment baseline against which investigational drugs are typically compared in clinical trials. Part 1 likely refers to an initial phase or component of a multi-part trial design used by CalciMedica.
Approved indications
Common side effects
Key clinical trials
- A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) (PHASE2, PHASE3)
- Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People With HIV Receiving Antiretroviral Therapy (PHASE1)
- A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) (PHASE3)
- Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors (PHASE1)
- Remission of Diabetes With Lifestyle Intervention for Malaysian Patients (NA)
- A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer (PHASE1, PHASE2)
- A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (PHASE2)
- A Digital Treatment Platform for the Delivery of Home-Based Sequential Therapy in Patients With Glioma (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard of Care (Part 1) CI brief — competitive landscape report
- Standard of Care (Part 1) updates RSS · CI watch RSS
- CalciMedica, Inc. portfolio CI
Frequently asked questions about Standard of Care (Part 1)
What is Standard of Care (Part 1)?
How does Standard of Care (Part 1) work?
Who makes Standard of Care (Part 1)?
Is Standard of Care (Part 1) also known as anything else?
What development phase is Standard of Care (Part 1) in?
Related
- Manufacturer: CalciMedica, Inc. — full pipeline
- Also known as: Placebo-Injectable Emulsion, Sinemet
- Compare: Standard of Care (Part 1) vs similar drugs
- Pricing: Standard of Care (Part 1) cost, discount & access